

SHAO-CHUN WANG (王紹椿)

POSITION/AFFILIATIONS PROFESSOR, COLLEGE OF MEDICINE DIRECTOR, RESEARCH CENTER FOR CANCER BIOLOGY INVESTIGATOR AND DEPUTY DIRECTOR, CENTER FOR MOLECULAR MEDICINE CHINA MEDICAL UNIVERSITY & HOSPITAL TAIWAN, R.O.C.	CONTACT INFORMATION Address: C1-6F., No. 350, Jingmao 1st Rd., Beitun Dist., Taichung City 406040, Taiwan (R.O.C.) TEL:04-22053366/7923 (Office)/7914 (Lab) E-mail: scpwang@mail.cmu.edu.tw		
EDUCATION			
INSTITUTION AND LOCATION	DEGREE	YEAR(S)	FIELD OF STUDY
Taipei College of Medicine, Taipei, Taiwan	B.S.	1988	Pharmacy
University of Minnesota Twin Cities, Minnesota, USA	Ph.D.	1995	Genetics and Cell Biology

Positions and Employment (含現職，由最近者往前追溯)

- 2023-present Deputy Director, Cancer Biology and Precision Therapeutics Center of Ministry of Education to the China Medical University
- 2019-present Director, Research Center for Cancer Biology, China Medical University
- 2019-2023 Vice Dean, College of Medicine, China Medical University
- 2016-present Deputy Director, Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
- 2016-present Professor, School of Medicine, China Medical University, Taichung, Taiwan
- 2016-present Adjunct Associate Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio, USA
- 2014-2016 Associate Professor of Cancer Biology, University of Cincinnati College of Medicine, Ohio, USA
- 2007-2014 Tenure-track Assistant Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio, USA

Selected publications (*corresponding author) (請擇代表著作，時間先後順序由最近者往前追溯)

1. Chen, C.-C., Li, H.-W., Wang, Y.-L., Lee, C.-C., Shen, Y.-C., Hsieh, C.-Y., Lin, H.-L., Chen, X.-X., Cho, D.-Y., Hsieh, C.-L., Guo, J.-H., Wei, S.-T., Wang, J., **Wang, S.-C.*** Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors. *Scientific Reports* 12(1), 16399, 2022.
2. Chu, Y.-Y., Chen, M.-K., Wei, Y., Lee, H.-H., Xia, W., Wang, Y.-N., Yam, C., Hsu, J.-L., Wang, H.-L., Chang, W.-C., Yamaguchi, H., Jiang, Z., Liu, C., Li, C.-F., Nie, L., Chan, L.-C., Gao, Y., **Wang, S.-C.**, Liu, J., Westin, S.-N., Lee, S., Sood, A.-K., Yang, L., Hortobagyi, G.-N., Yu, D., Hung, M.-C. Targeting the ALK/CDK9-Y19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. *Nature Cancer* 3(10), 1211-1227, 2022.
3. Liu, L.-C., Shen, Y.-C., Wang, Y.-L., Wu, W.-R., Chang, L.-C., Chen, Y.-H., Lee, C.-C.* **Wang, S.-C.*** Growth-promoting function of the cGAS-STING pathway in triple-negative breast cancer cells. *Frontiers in Oncology* 12, 851795, 2022.
4. Wang, Y.-L., Wu, W.-R., Lin, P.-L., Shen, Y.-C., Lin, Y.-Z., Li, H.-W., Hsu, K.-W., **Wang, S.-C.*** The functions of PCNA in tumor stemness and invasion. *International Journal of Molecular Sciences* 23(10), 5679, 2022.
5. Lin, Y.-Z., Liu, S.-H., Wu, W.-R., Shen, Y.-C., Wang, Y.-L., Liao, C.-C., Lin, P.-L., Chang, H., Liu, L.-C., Cheng, W.-C.* **Wang, S.-C.*** miR-4759 suppresses breast cancer through immune checkpoint blockade. *Computational and Structural Biotechnology Journal* 20, 241-251, 2022.
6. O-Y, F.* **Li, C.-L.**, Chen, C.-C., Shen, Y.-C., Moi, S.-H., Luo, C.-W., Xia, W., Wang, L.-H., **Wang, S.-C.***, Pan, M.-R.* **Hou, M.-F.***, Hung, M.-C.* De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. *American Journal of Cancer Research* 12(1), 123-137, 2022.
7. Wang, Y.-L., Lee, C.-C., Shen, Y.-C., Lin, P.-L., Wu, W.-R., Lin, Y.-Z., Cheng, W.-C., Chang, H., Hung, H., Cho, Y.-C., Liu, L.-C., Xia, W., Ji, J.-H., Liang, J.-A., Liu, C.-G., Yao, J., Hung, M.-C.* **Wang, S.-C.*** Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA. *Cell Reports* 36(8), 109537, 2021.